SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer.

SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer.

Future Oncol. 2018 Dec 04;:

Authors: Wu C, Tuo Y

Abstract
AIM: To explore the prognostic value of synaptonemal complex protein-2 (SYCP2) in different subtypes of breast cancer. Patients & materials: In silico bioinformatic analysis was conducted using large databases.
RESULTS: SYCP2 was only significantly upregulated in luminal B tumors compared with the adjacent normal tissues. SYCP2 expression was an independent indicator of shorter overall survival in luminal A patients (hazard ratio: 2.269; 95% CI: 1.059-4.862; p = 0.035) and luminal B patients (hazard ratio: 2.546; 95% CI: 1.020-6.355; p = 0.045). Its expression was negatively correlated with the methylation status of multiple CpG sites (cg22214414, cg23241473 and cg07347645) in both luminal A and luminal B tumors.
CONCLUSION: Increased SYCP2 expression might be an independent indicator of shorter overall survival in both luminal A and luminal B patients.

PMID: 30511892 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2E0T01v